Expert Panel consensus statements on the optimal usage of rituximab for the management of rheumatoid arthritis in India
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in RA. Rituximab is a well-established biologic for the ma...
Saved in:
Main Authors: | Keerthi Talari, Vinod Ravindran, Pradip Kumar, Pravin Patil, Sarath Chandra Mouli, Syamasis Bandyopadhyay, Balebail G Dharmanand, Abhrajit Ray, Shankaralingam Rajeshwari, Sanjiv N Amin, Jyotsna Oak, Ved Chaturvedi, Anand N Malaviya, Sukumar Mukherjee |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Indian Journal of Rheumatology |
Subjects: | |
Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2021;volume=16;issue=3;spage=311;epage=321;aulast=Talari |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01) -
A retrospective cohort study of biosimilar rituximab therapy in pemphigus: experience from a tertiary care hospital in North India
by: Sabha Mushtaq, et al.
Published: (2024-11-01) -
Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia
by: Mohammed Alqahtani, et al.
Published: (2024-11-01) -
Real life experience of a screening strategy for latent tuberculosis before treatment with biologicals in indian patients with rheumatic diseases
by: Anand N Malaviya, et al.
Published: (2018-01-01) -
Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)